Heart Failure at Admission Complicating ST-Elevation Myocardial Infarction in a Middle-Income Country. Experience of the ARGEN-IAM-ST Registry.

Despite advances in the management of ST-elevation myocardial infarction (STEMI), when associated with heart failure (HF) its prognosis remains ominous. This study assessed the differences in admission and mortality of HF complicating STEMI at admission (HFad) in a middle-income country. Data from the National Registry of STEMI of Argentina (ARGEN-IAM-ST) from January 1, 2016, to September 30, 2020, were analyzed. HFad was defined by the identification of Killip/Kimball ≥2 at admission. About 3174 patients were analyzed (22.3% had HFad). Patients with HFad were older, more often women, hypertensive, and diabetic. Received less reperfusion (87.6% vs 92.6%, P < 0.001) and had increased in-hospital mortality (28.4% vs 3.0%, P < 0.001). In multivariate analysis HFad was an independent predictor of death (OR: 4.88 [95%CI: 3.33-7.18], P < 0.001) and reperfusion adjusted to HFad was associated with lower mortality (OR: 0.57 [95%CI: 0.34-0.95], P = 0.03). HFad in STEMI is associated with a worse clinical profile, receives fewer reperfusion strategies, and carries a higher risk of in-hospital mortality while reperfusion reduces mortality.

Registro ARGEN-IAM-ST: infarto de miocardio con elevación del segmento ST en el "nuevo" adulto mayor / ARGEN-IAM-ST Registry: ST-elevation myocardial infarction in "new" older adults

RESUMEN Introducción: La Organización Mundial de la Salud (OMS) considera adulto mayor (AM) a las personas que tienen 60 años o más. Es sabido que la mortalidad por infarto agudo de miocardio (IAM) aumenta a edades más avanzadas, pero siempre se han utilizado umbrales de edad mayores que el propuesto por la OMS, por lo cual describir las características y evolución intrahospitalaria de este subgrupo (de acuerdo con la definición de la OMS) se torna relevante. Objetivos: 1) conocer la prevalencia de los AM según la OMS, con IAM con elevación del segmento ST en Argentina y 2) com- parar sus características, tratamientos de reperfusión y mortalidad con los adultos jóvenes. Material y métodos: Se analizaron los pacientes ingresados en el Registro Nacional de Infarto (ARGEN-IAM-ST). Se compara- ron las características clínicas, tratamientos y evolución de los AM y los adultos jóvenes. Resultados: Se incluyeron 6676 pacientes, de los cuales 3626 (54,3%) eran AM. Los AM fueron más frecuentemente mujeres (37,6% vs. 31,4%, p <0,001), hipertensos (67,8% vs. 47%, p <0,001), diabéticos (26,1% vs. 19,9%, p <0,001), dislipidémicos (45,4% vs. 37%, p <0,001), y tuvieron más antecedentes coronarios (16% vs. 10,3%, p <0,001). El tiempo a la consulta de los AM fue mayor (120 min vs. 105 min, p <0,001) con similar tiempo total de isquemia (314 min vs. 310 min, p = 0,33). Recibi- eron menos tratamiento de reperfusión (89,9% vs. 88,6%, p = 0,04) y más angioplastia primaria (91 % vs. 87,4%, p <0,001). Tuvieron más insuficiencia cardíaca (27,3% vs. 18,5%, p <0,001), similar incidencia de sangrado (3,7 vs. 3,1%, p = 0,33) y una mortalidad significativamente mayor (11,4% vs. 5,5%, p <0,001). Ser AM fue predictor independiente de mortalidad. Conclusiones: Más de la mitad de los IAM en nuestro país ocurren en AM. Los pacientes mayores tienen menor probabilidad de recibir reperfusión, más insuficiencia cardíaca y el doble de la mortalidad que los pacientes menores de 60 años.

ABSTRACT Background: The World Health Organization (WHO) defines an Older Adult (OA) as any individual aged 60 or older. It is known that mortality due to acute myocardial infarction (AMI) increases with age, but age thresholds higher than those proposed by the WHO have been consistently used; therefore, describing the characteristics and in-hospital progress of this subgroup of patients, in accordance with the WHO definition, becomes relevant. Objectives: 1) To know the prevalence of OA with acute ST-elevation myocardial infarction (STEMI) in Argentina according to the WHO, and 2) to compare their characteristics, reperfusion treatments, and mortality against those in young adults. Methods: Patients included in the National Registry of ST- Elevation Myocardial Infarction (Registro Nacional de Infarto con Elevación del ST, ARGEN-IAM-ST) were analyzed. Clinical features, therapies, and progress were compared in OA versus young adults. Results: A total of 6676 patients were enrolled, 3626 of which (54.3%) were OA. OA were mostly female (37.6% vs 31.4%, p <0.001), had hypertension (67.8% vs 47%, p <0.001), diabetes (26.1% vs 19.9%, p <0.001), dyslipidemia (45.4% vs 37%, p <0.001), and a longer coronary artery disease history (16% vs 10.3%, p < 0.001). The time to consultation in OA was longer (120 min vs 105 min, p <0.001), with a similar total ischemic time (314 min vs 310 min, p = 0.33). They received less reperfu- sion treatment (89.9% vs 88.6%, p = 0.04) and more primary angioplasty (91% vs 87.4%, p <0.001). Heart failure was more common in OAs (27.3% vs 18.5%, p <0.001), with a similar bleeding incidence (3.7% vs 3.1%, p = 0.33), and significantly higher mortality (11.4% vs 5.5%, p<0.001). Being an OA was an independent mortality predictor. Conclusions: More than half the cases of AMI in our country occur in OA. Older patients are less likely to receive reperfusion, more likely to have heart failure, and show twice the rate of mortality as compared to patients under 60.

Differential gene expression provides leads to environmentally regulated soybean seed protein content.

Soybean is an important global source of plant-based protein. A persistent trend has been observed over the past two decades that soybeans grown in western Canada have lower seed protein content than soybeans grown in eastern Canada. In this study, 10 soybean genotypes ranging in average seed protein content were grown in an eastern location (control) and three western locations (experimental) in Canada. Seed protein and oil contents were measured for all lines in each location. RNA-sequencing and differential gene expression analysis were used to identify differentially expressed genes that may account for relatively low protein content in western-grown soybeans. Differentially expressed genes were enriched for ontologies and pathways that included amino acid biosynthesis, circadian rhythm, starch metabolism, and lipid biosynthesis. Gene ontology, pathway mapping, and quantitative trait locus (QTL) mapping collectively provide a close inspection of mechanisms influencing nitrogen assimilation and amino acid biosynthesis between soybeans grown in the East and West. It was found that western-grown soybeans had persistent upregulation of asparaginase (an asparagine hydrolase) and persistent downregulation of asparagine synthetase across 30 individual differential expression datasets. This specific difference in asparagine metabolism between growing environments is almost certainly related to the observed differences in seed protein content because of the positive correlation between seed protein content at maturity and free asparagine in the developing seed. These results provided pointed information on seed protein-related genes influenced by environment. This information is valuable for breeding programs and genetic engineering of geographically optimized soybeans.

Utilización de la estrategia farmacoinvasiva en Argentina. Análisis del registro ARGEN-IAM ST / Use of the Pharmacoinvasive Strategy in Argentina. ARGEN-IAM ST Registry Analysis

RESUMEN Introducción : La angioplastia primaria (ATCp) es el tratamiento de elección para el infarto agudo de miocardio con elevación del segmento ST (IAMCEST). En nuestro país, de tanta extensión territorial y con tiempos a la reperfusión subóptimos, la estrategia farmacoinvasiva (Finv) podría considerarse. Material y métodos : El ARGEN-IAM-ST es un registro prospectivo, multicéntrico, nacional y observacional. Se incluyen pacien tes con IAMCEST dentro de las 36 horas de evolución. Se definió en el mismo la utilización de Finv y las variables asociadas. Resultados : Se analizaron 4788 pacientes de los cuales en el 88,56 % se realizó ATCp, en el 8,46 % trombolíticos con reperfusión positiva (TL+), y solo en un 2,98% Finv. La mediana y rango intercuartílico (RIC) del tiempo total de isquemia fueron menores en aquellos que recibieron TL+ (165 min, RIC 100-269) y los que fueron a Finv (191 min, RIC 100-330) que en aquellos que fueron a ATCp (280 min, RIC 179- 520), p <0,001. No existieron diferencias en mortalidad intrahospitalaria, en el grupo Finv 4,9%, 5,2% en el grupo TL + y en el grupo ATCp 7,8% (p = 0,081). No hubo diferencias en término de sangrados mayores. Se observó que un 57% de los pacientes con TL+ reunían características de alto riesgo, y no recibieron Finv acorde a lo recomendado Conclusiones : Solo 3 de cada 100 pacientes con IAMCEST que se reperfunden reciben Finv. Su implementación no está ligada en forma sistemática al alto riesgo de eventos. Pese a esta subutilización, por presentar un menor tiempo total de isquemia que la ATCp, sin aumento en los sangrados clínicamente relevantes persiste como una opción a considerar en nuestra realidad.

ABSTRACT Background : Primary percutaneous coronary intervention (PPCI) is the treatment of choice for acute ST-elevation myocardial infarction (STEMI). In Argentina, a country with a large area and suboptimal reperfusion times, the pharmacoinvasive (PI) strategy might be considered. Methods : ARGEN-IAM-ST is a national prospective, multicenter, and observational registry that includes STEMI patients with less than 36 hours of progression. The PI strategy usage and its associated variables were defined. Results : In this registry, 4788 patients were analyzed, of which 88.56% underwent PPCI, 8.46% received thrombolytics with positive reperfusion (TL+), and only 2.98% received PI strategy. Median and interquartile range (IQR) of total ischemia time were lower in patients receiving TL+ (165 min, IQR 100-269) and PI (191 min, IQR 100-330) than in patients undergoing PPCI (280 min, IQR 179-520), p <0.001. No differences in intra-hospital mortality were observed: 4.9% in the PI strategy group, 5.2% in the TL+ group and 7.8% in the PPCI group (p = 0.081). No differences in major bleeding events were observed. It was observed that 57% of the TL+ patients met the criteria for high cardiovascular risk, but they did not receive PI strategy, as recommended. Conclusions : Only 3 out of 100 reperfused STEMI patients received PI strategy. Its administration is not systematically associated to high cardiovascular risk. Despite the under-usage, it remains an option to be considered due to its total ischemia time lower than in the PPCI, with no increase in clinically significant bleedings.

GmSWEET29 and Paralog GmSWEET34 Are Differentially Expressed between Soybeans Grown in Eastern and Western Canada.

Over the past two decades soybeans grown in western Canada have persistently had lower seed protein than those grown in eastern Canada. To understand the discrepancy in seed protein content between eastern- and western-grown soybeans, RNA-seq and differential expression analysis have been investigated. Ten soybean genotypes, ranging from low to high in seed protein content, were grown in four locations across eastern (Ottawa) and western (Morden, Brandon, and Saskatoon) Canada. Differential expression analysis revealed 34 differentially expressed genes encoding Glycine max Sugars Will Eventually be Exported Transporters (GmSWEETs), including paralogs GmSWEET29 and GmSWEET34 (AtSWEET2 homologs) that were consistently upregulated across all ten genotypes in each of the western locations over three years. GmSWEET29 and GmSWEET34 are likely candidates underlying the lower seed protein content of western soybeans. GmSWEET20 (AtSWEET12 homolog) was downregulated in the western locations and may also play a role in lower seed protein content. These findings are valuable for improving soybean agriculture in western growing regions, establishing more strategic and efficient agricultural practices.

Generation of a mouse model of the neurodevelopmental disorder with dysmorphic facies and distal limb anomalies syndrome.

Heterozygous variants in bromodomain and plant homeodomain containing transcription factor (BPTF) cause the neurodevelopmental disorder with dysmorphic facies and distal limb anomalies (NEDDFL) syndrome (MIM#617755) characterized by intellectual disability, speech delay and postnatal microcephaly. BPTF functions within nucleosome and remodeling factor (NURF), a complex comprising sucrose non-fermenting like (SNF2L), an Imitation SWItching (ISWI) chromatin remodeling protein encoded by the SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 1 (SMARCA1) gene. Surprisingly, ablation of Smarca1 resulted in mice with enlarged brains, a direct contrast to the phenotype of NEDDFL patients. To model the NEDDFL syndrome, we generated forebrain-specific Bptf knockout (Bptf conditional Knockout (cKO)) mice. The Bptf cKO mice were born in normal Mendelian ratios, survived to adulthood but were smaller in size with severe cortical hypoplasia. Prolonged progenitor cell cycle length and a high incidence of cell death reduced the neuronal output. Cortical lamination was also disrupted with reduced proportions of deep layer neurons, and neuronal maturation defects that impaired the acquisition of distinct cell fates (e.g. COUP-TF-interacting protein 2 (Ctip2)+ neurons). RNAseq and pathway analysis identified altered expression of fate-determining transcription factors and the biological pathways involved in neural development, apoptotic signaling and amino acid biosynthesis. Dysregulated genes were enriched for MYC Proto-Oncogene, BHLH Transcription Factor (Myc)-binding sites, a known BPTF transcriptional cofactor. We propose the Bptf cKO mouse as a valuable model for further study of the NEDDFL syndrome.

Valor pronóstico del índice de shock en el infarto de miocardio. Datos del Registro Argentino de infarto con elevación del segmento ST (ARGEN IAM-ST) / Prognostic value of the shock index in myocardial infarction. Data from Argentine Registry of ST-segment elevation infarct (ARGEN IAM-ST)

Resumen El índice de shock (IS) se obtiene mediante un cálculo simple del cociente entre la frecuencia cardíaca (FC) y la tensión arterial sistólica (PAS) (IS: FC/TAS) y el índice de shock ajustado por edad (ISA) multiplicando el IS x edad. Evaluamos su valor predictivo para el evento combinado intrahospitalario (EC) muerte y/o shock cardiogénico (SC) y de los eventos individuales en los pacientes incluidos en el registro argentino de infarto con elevación del segmento ST (ARGEN-IAM-ST). Se excluyeron 248 con SC de ingreso. Se realizaron curvas ROC para ambos índices utilizando el mejor punto de corte para dicotomizar la población. Se incluyeron 2928 pacientes. Edad (mediana) 60 años (RIC 25-75% 53-68), varones 80%, EC: 6.4%. Un 30.5% tuvo IS ≥ 0.67 y éstos presentaron mayor incidencia de EC: 11% vs. 4% (p < 0.001), shock cardiogénico (8% vs. 2.6%, p <0.0001) y muerte (7.3% vs. 3%, p < 0.0001) que los pacientes con IS < 0.67. Un 28% tuvo ISA ≥ 41.5. Estos presentaron más EC: 14% vs. 3%, p < 0.001, SC: 10% vs. 2%, (p < 0.001) y muerte: 9.5% vs. 2.3%, (p < 0.001) comparados con los pacientes con valores ISA < 41.5. El área bajo la curva ROC del ISA para EC fue significativamente mejor que la del IS (0.72 vs. 0.62, p < 0.001).En los modelos de análisis multivariados reali zados, el IS tuvo un OR de 2.56 (IC95% 1.56-4.02; p < 0.001) y el ISA de 3.43 (IC95% 2.08-5.65; p<0.001) para EC. El IS y el ISA predicen muerte y/o el desarrollo de shock cardiogénico intrahospitalario en una población no seleccionada de infartos con elevación del ST.

Abstract The shock index (IS) is the quotient between the heart rate (HR) and the systolic blood pressure (SBP) (IS: HR / SBT), and the age-adjusted shock index (ISA) multiplying the IS by age. We evaluated its predictive value for the combined in-hospital event (EC), death and / or cardiogenic shock (CS) and for individual events in the patients included in the Argentine registry of ST-segment elevation infarction (ARGEN-ST-AMI); 248 with CS on admission were excluded. ROC curves were made for both indices using the best cut-off point to dichotomize the population. The analysis included 2928 subjects. Age (median) 60 years (IQR 25-75% 53-68), men 80%, EC: 6.4%; 30.5% had IS ≥ 0.67, and they had a higher incidence of EC: 11% vs. 4% (p < 0.001), cardiogenic shock (8% vs. 2.6%, p <0.0001) and death (7.3% vs. 3%), p <0.0001) than patients with IS < 0.67. A 28% had ISA ≥ 41.5. These presented plus EC: 14% vs. 3%, p < 0.001, SC: 10% vs. 2%, (p < 0.001) and death: 9.5% vs. 2.3%, (p < 0.001) compared with patients with values < 41.5. The area under the ROC curve of the ISA for EC was significantly better than that of the IS (0.72 vs. 0.62, p < 0.001). In the multivariate analysis models performed, the IS had an OR: 2.56 (95% CI 1.56-4.02; p < 0.001) and the ISA: 3.43 (95% CI 2.08-5.65; p < 0.001) for EC. The IS and ISA predict death and / or the development of in-hospital cardiogenic shock in an unselected population of ST elevation infarcts.

[Prognostic value of the shock index in myocardial infarction. Data from Argentine Registry of ST-segment elevation infarct (ARGEN IAM-ST)]. / Valor pronóstico del índice de shock en el infarto de miocardio. Datos del Registro Argentino de infarto con elevación del segmento ST (ARGEN IAM-ST).

The shock index (IS) is the quotient between the heart rate (HR) and the systolic blood pressure (SBP) (IS: HR / SBT), and the age-adjusted shock index (ISA) multiplying the IS by age. We evaluated its predictive value for the combined in-hospital event (EC), death and / or cardiogenic shock (CS) and for individual events in the patients included in the Argentine registry of ST-segment elevation infarction (ARGEN-ST-AMI); 248 with CS on admission were excluded. ROC curves were made for both indices using the best cut-off point to dichotomize the population. The analysis included 2928 subjects. Age (median) 60 years (IQR 25-75% 53-68), men 80%, EC: 6.4%; 30.5% had IS = 0.67, and they had a higher incidence of EC: 11% vs. 4% (p < 0.001), cardiogenic shock (8% vs. 2.6%, p <0.0001) and death (7.3% vs. 3%), p <0.0001) than patients with IS < 0.67. A 28% had ISA = 41.5. These presented plus EC: 14% vs. 3%, p < 0.001, SC: 10% vs. 2%, (p < 0.001) and death: 9.5% vs. 2.3%, (p < 0.001) compared with patients with values < 41.5. The area under the ROC curve of the ISA for EC was significantly better than that of the IS (0.72 vs. 0.62, p < 0.001). In the multivariate analysis models performed, the IS had an OR: 2.56 (95% CI 1.56-4.02; p < 0.001) and the ISA: 3.43 (95% CI 2.08-5.65; p < 0.001) for EC. The IS and ISA predict death and / or the development of in-hospital cardiogenic shock in an unselected population of ST elevation infarcts.

El índice de shock (IS) se obtiene mediante un cálculo simple del cociente entre la frecuencia cardíaca (FC) y la tensión arterial sistólica (PAS) (IS: FC/TAS) y el índice de shock ajustado por edad (ISA) multiplicando el IS x edad. Evaluamos su valor predictivo para el evento combinado intrahospitalario (EC) muerte y/o shock cardiogénico (SC) y de los eventos individuales en los pacientes incluidos en el registro argentino de infarto con elevación del segmento ST (ARGEN-IAM-ST). Se excluyeron 248 con SC de ingreso. Se realizaron curvas ROC para ambos índices utilizando el mejor punto de corte para dicotomizar la población. Se incluyeron 2928 pacientes. Edad (mediana) 60 años (RIC 25-75% 53-68), varones 80%, EC: 6.4%. Un 30.5% tuvo IS = 0.67 y éstos presentaron mayor incidencia de EC: 11% vs. 4% (p < 0.001), shock cardiogénico (8% vs. 2.6%, p <0.0001) y muerte (7.3% vs. 3%, p < 0.0001) que los pacientes con IS < 0.67. Un 28% tuvo ISA = 41.5. Estos presentaron más EC: 14% vs. 3%, p < 0.001, SC: 10% vs. 2%, (p < 0.001) y muerte: 9.5% vs. 2.3%, (p < 0.001) comparados con los pacientes con valores ISA < 41.5. El área bajo la curva ROC del ISA para EC fue significativamente mejor que la del IS (0.72 vs. 0.62, p < 0.001).En los modelos de análisis multivariados realizados, el IS tuvo un OR de 2.56 (IC95% 1.56-4.02; p < 0.001) y el ISA de 3.43 (IC95% 2.08-5.65; p <0.001) para EC. El IS y el ISA predicen muerte y/o el desarrollo de shock cardiogénico intrahospitalario en una población no seleccionada de infartos con elevación del ST.

A Multi-Year, Multi-Cultivar Approach to Differential Expression Analysis of High- and Low-Protein Soybean (Glycine max).

Soybean (Glycine max (L.) Merr.) is among the most valuable crops based on its nutritious seed protein and oil. Protein quality, evaluated as the ratio of glycinin (11S) to ß-conglycinin (7S), can play a role in food and feed quality. To help uncover the underlying differences between high and low protein soybean varieties, we performed differential expression analysis on high and low total protein soybean varieties and high and low 11S soybean varieties grown in four locations across Eastern and Western Canada over three years (2018-2020). Simultaneously, ten individual differential expression datasets for high vs. low total protein soybeans and ten individual differential expression datasets for high vs. low 11S soybeans were assessed, for a total of 20 datasets. The top 15 most upregulated and the 15 most downregulated genes were extracted from each differential expression dataset and cross-examination was conducted to create shortlists of the most consistently differentially expressed genes. Shortlisted genes were assessed for gene ontology to gain a global appreciation of the commonly differentially expressed genes. Genes with roles in the lipid metabolic pathway and carbohydrate metabolic pathway were differentially expressed in high total protein and high 11S soybeans in comparison to their low total protein and low 11S counterparts. Expression differences were consistent between East and West locations with the exception of one, Glyma.03G054100. These data are important for uncovering the genes and biological pathways responsible for the difference in seed protein between high and low total protein or 11S cultivars.

RACCOVID-19: primer Registro Argentino de Complicaciones Cardiovasculares en pacientes con COVID-19 / RACCOVID-19: First Argentine Registry of Cardiovascular Complications in COVID-19 Patients

RESUMEN Introducción: La enfermedad por coronavirus (COVID-19) ha causado una de las mayores pandemias conocidas al día de la fecha. La Sociedad Argentina de Cardiología (SAC) y la Federación Argentina de Cardiología (FAC) elaboraron el primer Registro Argentino de Complicaciones Cardiovasculares en pacientes con COVID-19 (RACCOVID-19), con el propósito de relevar, a nivel nacional, su impacto en la evolución hospitalaria de estos pacientes. Objetivos: Documentar la aparición de complicaciones cardiovasculares en pacientes internados por COVID-19 y evaluar predictores de riesgo de dichas complicaciones y su impacto pronóstico. Material y Métodos: Se incluyen datos de 2750 pacientes en 50 centros de 11 provincias del país, desde el 18 de mayo hasta el 31 de octubre de 2020. Resultados: La edad promedio fue de 57±18 años y hubo predominio de sexo masculino (60,2%). La tasa de complicaciones cardiovasculares fue del 15,3%. La insuficiencia cardíaca (43,5%), las arritmias (33,5%) y el daño miocárdico (31,1%) fueron las complicaciones más frecuentes. La mortalidad fue del 19,3%. Un modelo de predicción de sobrevida en la etapa hospitalaria incluyó las siguientes variables: edad, sexo masculino, valores de hematocrito y creatinina al ingreso, existencia de antecedentes patológicos, formas de presentación de COVID-19 graves y presencia de complicaciones cardiovasculares. Conclusiones: El registro RACCOVID-19 mostró una tasa de complicaciones cardiovasculares del 15,3%. La mortalidad total del registro fue del 19,3% y las complicaciones cardiovasculares junto con otras variables de presentación, así como la gravedad del cuadro clínico de COVID-19, forman parte de un perfil de riesgo clínico asociado a mayor mortalidad.

ABSTRACT Background: Coronavirus disease (COVID-19) has caused one of the largest pandemics known to date. The Argentine Society of Cardiology (SAC) and the Argentine Federation of Cardiology (FAC) have developed the First Argentine Registry of Cardiovascular Complications in COVID-19 patients (RACCOVID-19) with the purpose of performing a nationwide review of their impact in the in-hospital evolution of these patients. Objectives: The aim of this study was to record cardiovascular complications in hospitalized patients for COVID-19, and to evaluate risk predictors of these complications and their prognostic impact. Methods: A total of 2750 patients from 50 centers in 11 provinces of the country were included from May 18 to October 31, 2020. Results: Mean age was 57±18 years, with a prevalence of male gender (60.2%). Cardiovascular complications occurred in 15.3% of cases. Heart failure (43.5%), arrhythmias (33.5%) and myocardial injury (31.1%) were the most relevant complications. Mortality was 19.3%, and a predictive model of in-hospital survival included age, male gender, admission hematocrit and creatinine, history of previous diseases, severe forms of COVID-19 presentation and cardiovascular complications. Conclusions: The RACCOVID-19 registry showed 15.3% of cardiovascular complications. Overall mortality was 19.3% and cardiovascular complications together with other presentation variables as well as the clinical severity of COVID-19, are part of a clinical risk profile associated with higher mortality.

Impaired SNF2L Chromatin Remodeling Prolongs Accessibility at Promoters Enriched for Fos/Jun Binding Sites and Delays Granule Neuron Differentiation.

Chromatin remodeling proteins utilize the energy from ATP hydrolysis to mobilize nucleosomes often creating accessibility for transcription factors within gene regulatory elements. Aberrant chromatin remodeling has diverse effects on neuroprogenitor homeostasis altering progenitor competence, proliferation, survival, or cell fate. Previous work has shown that inactivation of the ISWI genes, Smarca5 (encoding Snf2h) and Smarca1 (encoding Snf2l) have dramatic effects on brain development. Smarca5 conditional knockout mice have reduced progenitor expansion and severe forebrain hypoplasia, with a similar effect on the postnatal growth of the cerebellum. In contrast, Smarca1 mutants exhibited enlarged forebrains with delayed progenitor differentiation and increased neuronal output. Here, we utilized cerebellar granule neuron precursor (GNP) cultures from Smarca1 mutant mice (Ex6DEL) to explore the requirement for Snf2l on progenitor homeostasis. The Ex6DEL GNPs showed delayed differentiation upon plating that was not attributed to changes in the Sonic Hedgehog pathway but was associated with overexpression of numerous positive effectors of proliferation, including targets of Wnt activation. Transcriptome analysis identified increased expression of Fosb and Fosl2 while ATACseq experiments identified a large increase in chromatin accessibility at promoters many enriched for Fos/Jun binding sites. Nonetheless, the elevated proliferation index was transient and the Ex6DEL cultures initiated differentiation with a high concordance in gene expression changes to the wild type cultures. Genes specific to Ex6DEL differentiation were associated with an increased activation of the ERK signaling pathway. Taken together, this data provides the first indication of how Smarca1 mutations alter progenitor cell homeostasis and contribute to changes in brain size.

Transgenic mice with an R342X mutation in Phf6 display clinical features of Börjeson-Forssman-Lehmann Syndrome.

The PHF6 mutation c.1024C > T; p.R342X, is a recurrent cause of Börjeson-Forssman-Lehmann Syndrome (BFLS), a neurodevelopmental disorder characterized by moderate-severe intellectual disability, truncal obesity, gynecomastia, hypogonadism, long tapering fingers and large ears (MIM#301900). Here, we generated transgenic mice with the identical substitution (R342X mice) using CRISPR technology. We show that the p.R342X mutation causes a reduction in PHF6 protein levels, in both human and mice, from nonsense-mediated decay and nonsense-associated alternative splicing, respectively. Magnetic resonance imaging studies indicated that R342X mice had a reduced brain volume on a mixed genetic background but developed hydrocephaly and a high incidence of postnatal death on a C57BL/6 background. Cortical development proceeded normally, while hippocampus and hypothalamus relative brain volumes were altered. A hypoplastic anterior pituitary was also observed that likely contributes to the small size of the R342X mice. Behavior testing demonstrated deficits in associative learning, spatial memory and an anxiolytic phenotype. Taken together, the R342X mice represent a good preclinical model of BFLS that will allow further dissection of PHF6 function and disease pathogenesis.

[Primary angioplasty in Argentina. Results from ARGEN-IAM-ST registry]. / Angioplastia primaria en Argentina. Registro ARGEN-IAM-ST (Relevamiento Nacional del infarto agudo de miocardio con elevación del segmento ST).

Our objective was to evaluate clinical characteristics, results and morbi-mortality in primary angioplasty (PA), of patients treated with PA within 36 hours of a myocardial infarction (MI), included in a prospective, transversal, multicenter and national survey (ARGEN-IAM-ST). A total of 1142 patients treated with PA were registered, 61.2 ± 12 years old, 88% male, 20% diabetics and 58% with hypertension; 77.6% in Killip Kimball I and 6.2% in cardiogenic shock. The time from the onset of pain until admission was 153 (75-316) minutes, and door-balloon of 91 (60-150) minutes. The transferred patients (17%) showed longer delay to admission, 200 minutes (195-420; p = 0.0001) and door-to-balloon 113.5 minutes (55-207); p = 0.099. In 47.6% of the cases, the PA was made in the anterior descending artery, in 36.4% in the right coronary artery, in 14.8% in the circumflex artery and in 1.2% in the left coronary artery; in 95% with stent (29% pharmacological); 95% was successful, 1.3% presented post-infarct angina (APIAM), 1.3% re-infarct, 8.8% shock and 3.2% bleeding. Age > 64 years (OR 6.2 (95% CI: 3.2-12), p <0.001), diabetes (OR 2.5, 95% CI 1.6-3.9, p < 0.001), re-infarction or APIAM (OR 3.3, 95% CI 1.3-8.3, p = 0.011) and shock (OR 29.2 (15.6-54.8), p < 0.001) were independently associated with higher mortality. In-hospital mortality of acute myocardial infarction with ST-segment elevation treated with PA was 7.6%. Transference from other center was associated with delay in the admission and treatment. Cardiogenic shock and post-infarct ischemia were associated with high mortality. There were no procedural variables associated with mortality.

Se evaluaron las características clínicas, demoras, resultados y morbimortalidad de 1142 pacientes tratados con angioplastia primaria (AP) dentro de las 36 horas del infarto, incluidos en el registro ARGEN-IAM-ST, de carácter prospectivo, transversal, multicéntrico y de alcance nacional. Edades: 61.2 ± 12 años, 88% varones, 20% diabéticos y 58% hipertensos; 77.6% en Killip y Kimball I y 6.2% en shock cardiogénico. El tiempo desde el inicio del dolor hasta el ingreso fue de 153 (75-316) minutos, y puerta-balón de 91 (60-150) minutos. Los casos derivados (17%) tuvieron mayor demora de ingreso, 200 minutos (195-420; p = 0.0001) y mayor tiempo puerta-balón, 113 minutos (55-207); p = 0.099. En 47.6% de los casos la AP se hizo en arteria descendente anterior, en 36.4% a coronaria derecha, en 14.8% a circunfleja y en 1.2% al tronco de coronaria izquierda; en 95% con stent (29% farmacológico). El 95% fue exitoso. El 1.3% presentó angina post-infarto (APIAM), 1.3% re-infarto, 8.8% shock y 3.2% sangrado. Se asociaron a mayor mortalidad edad > 64 años (OR 6.2 (IC 95%: 3.2-12), p < 0.001), diabetes (OR 2.5, IC 95% 1.6-3.9, p < 0.001), re-infarto o APIAM (OR 3.3, IC 95% 1.3-8.3, p = 0.011) y shock (OR 29.2 (15.6-54.8), p < 0.001). La mortalidad hospitalaria del infarto agudo de miocardio con elevación del segmento ST tratado con AP fue de 7.6%. La derivación se asoció a demora de tratamiento. El shock cardiogénico y la isquemia post-infarto se asociaron a alta mortalidad. No hubo variables del procedimiento asociadas a mortalidad.

Angioplastia primaria en Argentina. Registro ARGEN-IAM-ST (relevamiento nacional del infarto agudo de miocardio con elevación del segmento ST) / Primary angioplasty in Argentina. Results from ARGEN-IAM-ST registr

Se evaluaron las características clínicas, demoras, resultados y morbimortalidad de 1142 pacientes tratados con angioplastia primaria (AP) dentro de las 36 horas del infarto, incluidos en el registro ARGEN-IAM-ST, de carácter prospectivo, transversal, multicéntrico y de alcance nacional. Edades: 61.2 ± 12 años, 88% varones, 20% diabéticos y 58% hipertensos; 77.6% en Killip y Kimball I y 6.2% en shock cardiogénico. El tiempo desde el inicio del dolor hasta el ingreso fue de 153 (75-316) minutos, y puerta-balón de 91 (60-150) minutos. Los casos derivados (17%) tuvieron mayor demora de ingreso, 200 minutos (195-420; p = 0.0001) y mayor tiempo puerta-balón, 113 minutos (55-207); p = 0.099. En 47.6% de los casos la AP se hizo en arteria descendente anterior, en 36.4% a coronaria derecha, en 14.8% a circunfleja y en 1.2% al tronco de coronaria izquierda; en 95% con stent (29% farmacológico). El 95% fue exitoso. El 1.3% presentó angina post-infarto (APIAM), 1.3% re-infarto, 8.8% shock y 3.2% sangrado. Se asociaron a mayor mortalidad edad > 64 años (OR 6.2 (IC 95%: 3.2-12), p < 0.001), diabetes (OR 2.5, IC 95% 1.6-3.9, p < 0.001), re-infarto o APIAM (OR 3.3, IC 95% 1.3-8.3, p = 0.011) y shock (OR 29.2 (15.6-54.8), p < 0.001). La mortalidad hospitalaria del infarto agudo de miocardio con elevación del segmento ST tratado con AP fue de 7.6%. La derivación se asoció a demora de tratamiento. El shock cardiogénico y la isquemia post-infarto se asociaron a alta mortalidad. No hubo variables del procedimiento asociadas a mortalidad.

Our objective was to evaluate clinical characteristics, results and morbi-mortality in primary angioplasty (PA), of patients treated with PA within 36 hours of a myocardial infarction (MI), included in a prospective, transversal, multicenter and national survey (ARGEN-IAM-ST). A total of 1142 patients treated with PA were registered, 61.2 ± 12 years old, 88% male, 20% diabetics and 58% with hypertension; 77.6% in Killip Kimball I and 6.2% in cardiogenic shock. The time from the onset of pain until admission was 153 (75-316) minutes, and door-balloon of 91 (60-150) minutes. The transferred patients (17%) showed longer delay to admission, 200 minutes (195-420; p = 0.0001) and door-to-balloon 113.5 minutes (55-207); p = 0.099. In 47.6% of the cases, the PA was made in the anterior descending artery, in 36.4% in the right coronary artery, in 14.8% in the circumflex artery and in 1.2% in the left coronary artery; in 95% with stent (29% pharmacological); 95% was successful, 1.3% presented post-infarct angina (APIAM), 1.3% re-infarct, 8.8% shock and 3.2% bleeding. Age > 64 years (OR 6.2 (95% CI: 3.2-12), p <0.001), diabetes (OR 2.5, 95% CI 1.6-3.9, p < 0.001), re-infarction or APIAM (OR 3.3, 95% CI 1.3-8.3, p = 0.011) and shock (OR 29.2 (15.6-54.8), p < 0.001) were independently associated with higher mortality. In-hospital mortality of acute myocardial infarction with ST-segment elevation treated with PA was 7.6%. Transference from other center was associated with delay in the admission and treatment. Cardiogenic shock and post-infarct ischemia were associated with high mortality. There were no procedural variables associated with mortality.

Registro prospectivo de tratamiento antitrombótico en coronarios agudos (EPICOR) / Prospective Registry of Antithrombotic Therapy in Acute Coronary Syndromes (EPICOR)

RESUMEN Objetivo: Presentar los resultados a dos años de seguimiento de la cohorte argentina del estudio EPICOR, un registro internacional, multicéntrico, observacional, prospectivo, diseñado para determinar los patrones de utilización de la terapia antitrombótica en pacientes con síndrome coronario agudo en el contexto de la práctica clínica habitual. Material y métodos: Se enrolaron 438 pacientes consecutivos con infarto de miocardio con supradesnivel del segmento ST (STEMI, 41%) o SCA sin supradesnivel del segmento ST (NSTE-ACS, 59%), externados vivos de centros hospitalarios públicos, privados y de comunidad. La media de edad fue 62 años, el 76% eran varones, el 71% hipertensos, el 64% fumadores, el 19% diabéticos y el 40% tenían antecedentes de patología cardiovascular previa. Resultados: La mortalidad global fue del 4,8% al año y del 7,3% a los 2 años. El uso de doble antiagregación plaquetaria fue del 80% al año y del 53% a los 2 años (p < 0,0001), sin diferencias entre aquellos con supradesnivel del ST o sin este. La incidencia de eventos isquémicos y hemorrágicos mayores a los 2 años fue del 15,3% y del 1,8%, respectivamente. Conclusiones: Se observó un elevado porcentaje de persistencia de la doble antiagregación plaquetaria a los 2 años, más allá del año recomendado por las guías, con baja incidencia de hemorragias mayores, lo que sugiere una selección clínica de riesgo-beneficio.

ABSTRACT Objectives: To present the two-year follow-up resultis of the EPICOR study Argentine cohort, a prospective, international, observational, multicenter registry designed to determine the use of antithrombotic therapy patterns in the routine clinical practice of patientis with acute coronary syndrome (ACS). Methods: The study enrolled a total of 438 consecutive patientis with ST-segment elevation myocardial infarction (STEMI, 41%) or non-ST-segment elevation ACS (NSTE ACS, 59%) discharged alive from public, private, and community hospitals. Mean age was 62 years, 76% of patientis were male, 71% hypertensive, 64% smokers, 19% diabetic and 40% had history of previous cardiovascular disease. Resultis: Overall mortality was 4.8% at 1 year and 7.3% at 2 years. Use of dual antiplatelet therapy was 80% at one year and 53% at 2 years (p<0.0001), with no differences between those with or without ST-segment elevation. The 2-year incidence of ischemic and major bleeding eventis was 15.3% and 1.8%, respectively Conclusions: Beyond the one-year administration recommended by the guidelines, a high percentage of persistent dual antiplatelet therapy was observed at 2 years, with a low incidence of major bleeding eventis, suggesting a clinical risk-benefit selection.

Pacientes con infarto agudo de miocardio con elevación del ST trasladados a centros con hemodinamia. Encuesta Nacional de Infarto Agudo de Miocardio con Elevación del ST en la República Argentina (ARGEN-IAM-ST) / Patients with ST-Segment Elevation Acute Myocardial Infarction Transferred to Centers with Percutaneous Coronary Intervention Capabilities. National Survey of ST-Segment Elevation Acute Myocardial Infarction in Argentina (ARGEN-IAM-ST)

Introducción: En la Argentina se ha incrementado progresivamente el uso de angioplastia primaria como estrategia de reperfusión en los pacientes con infarto agudo de miocardio y elevación del segmento ST (IAMCEST) sobre la base de redes formales o informales de derivación. No se han explorado en forma universal en nuestro país la funcionalidad y las demoras generadas por las derivaciones. Objetivos: Evaluar la frecuencia con que los pacientes con IAMCEST son derivados a centros con hemodinamia, la estrategia de reperfusión adoptada (angioplastia primaria, terapéutica trombolítica, angioplastia de rescate y farmacoinvasiva) y las demoras en el sistema. Material y métodos: Estudio prospectivo, observacional, multicéntrico, llevado a cabo en 247 centros de todas las provincias de la República Argentina. Desde marzo a diciembre de 2015 se incluyeron 1.661 pacientes con diagnóstico de IAMCEST de hasta 36 horas de evolución. Resultados: La edad promedio de los pacientes fue de 61 ± 11,9 años y el 77,6% eran de sexo masculino. La prevalencia promedio de derivación de todo el país desde otros centros para realizar tratamiento de reperfusión fue del 37% (IC 95% 34,80-39,44). Comparando los pacientes derivados con los tratados in situ, la aplicación global de tratamientos de reperfusión fue menor en los derivados [80% vs. 86% (OR 0,65; IC 95% 0,50-0,84; p < 0,001)]. Considerando solo los tratados con estrategias de reperfusión, en los derivados se utilizó menos angioplastia primaria [71% vs. 83% (OR 0,51; IC 95% 0,39-0,67)] y mayor aplicación de trombolíticos [29% vs. 17% (OR 1,92; IC 95% 1,48-2,50)] (p < 0,001). La angioplastia de rescate se realizó en 41 pacientes derivados versus 12 pacientes tratados en el primer centro de contacto y el tratamiento farmacoinvasivo en solo 12 pacientes, de los cuales 6 eran derivados de otro centro. El tiempo total de isquemia desde el comienzo de los síntomas hasta la realización de la angioplastia primaria fue de 350 minutos (RIC 25-75: 235-650) para los pacientes derivados y de 245 minutos (RIC 25/75: 170-450) para los pacientes tratados en el centro de primera consulta (p < 0,001). El tiempo puerta-balón fue de 85 minutos (RIC 25/75: 50-153) versus 95 minutos (RIC 25/75: 62-150) en los derivados y los no derivados, respectivamente (p = 0,01). En los pacientes derivados, el tiempo síntoma-aguja en los tratados con trombolíticos previo a la derivación fue de 165 minutos y en los derivados a angioplastia primaria, el tiempo síntoma-balón fue de 350 minutos, una diferencia de 185 minutos. La demora entre el acceso a la trombólisis in situ y la angioplastia derivada fue de 140 minutos. Conclusiones: En nuestro país, uno de cada tres pacientes con IAMCEST es derivado a otro centro para realizar tratamiento de reperfusión miocárdica. Los pacientes derivados tienen menos probabilidad de recibir tratamiento de reperfusión y menor utilización de angioplastia primaria. La diferencia de tiempo entre los pacientes que recibieron trombólisis previa a la derivación y la espera para realizar una angioplastia primaria supera las dos horas. El tratamiento farmacoinvasivo fue mínimo. La disponibilidad de recursos en los centros participantes indica que una mejor articulación de las redes de derivación podría mejorar los tiempos de acceso al tratamiento y disminuir la morbimortalidad del IAMCEST en la Argentina.

Variables asociadas con la mejoría de la función ventricular luego de la revascularización miocárdica / Variables Associated with Improved Left Ventricular Function After Myocardial Revascularization

Introducción: La revascularización miocárdica es el tratamiento de elección en pacientes con disfunción sistólica isquémica. La fracción de eyección del ventrículo izquierdo (FEVI) constituye un factor pronóstico en estos pacientes, por lo que resulta de interés identificar las variables relacionadas con la mejoría de la función ventricular. Objetivo: Determinar las variables asociadas con el restablecimiento de la FEVI en pacientes con disfunción ventricular isquémica sometidos a revascularización miocárdica. Material y métodos: Se evaluaron pacientes con FEVI < 50% sometidos a revascularización quirúrgica y con seguimiento ecocardiográfico > 6 meses. Se analizaron variables relacionadas con la mejoría de la FEVI (> 5%). Resultados: Se incluyeron 95 pacientes, 91,6% de sexo masculino, edad media de 63 años, 40% diabéticos, 27% con infarto previo y FEVI del 36% ± 6%. Se evaluó viabilidad en el 78%. Durante el posoperatorio, el 12% presentaron isquemia perioperatoria y el 28%, bajo gasto cardíaco. Tras análisis multivariado, la viabilidad y la ausencia de isquemia perioperatoria fueron predictores independientes de la mejoría de la FEVI. Conclusiones: La viabilidad y la falta de isquemia durante el perioperatorio se asociaron con mejoría de la FEVI durante el posoperatorio alejado.

Background: Myocardial revascularization is the treatment of choice in patients with systolic dysfunction due to ischemia. Left ventricular ejection fraction (LVEF) constitutes a prognostic factor in these patients; thus it may be interesting to identify the variables related with left ventricular function improvement. Objective: The aim of this study is to determine the variables associated with improvement of LVEF in patients with coronary artery disease and systolic dysfunction undergoing myocardial revascularization. Methods: We included patients with LVEF <50% undergoing surgical myocardial revascularization with echocardiographic monitoring >6 months. The variables associated with LVEF improvement >5% were analyzed. Results: The cohort was made up of 95 patients; 91.6% were men, mean age was 63 years, 40% were diabetics, 27% had previous myocardial infarction and LVEF was 36%±6%. Viability was assessed in 78%. During the immediate postoperative period, 12.6% presented ischemia and 28% presented low cardiac output. Multivariate analysis revealed that myocardial viability and the lack of perioperative ischemia were independent predictors of improved LVEF. Conclusions: Myocardial viability and absence of perioperative ischemia were associated with improved LVEF during long-term follow-up.

Prognostic Value of Infarct size Measured by Gated sPECT scintigraphy / Valor pronóstico del tamaño del infarto de miocardio cuantificado mediante SPECT gatillada

Background: Despite the improved sensitivity and specificity of SPECT myocardial perfusion imagingto detect myocardial involve-ment after acute myocardial infarction (AMI), there is little information about the usefulness of early infarct size (IS) measurement by this method for risk stratification and prognosis. Objectives: The goal of this study was to evaluate the usefulness of quantifying IS by gated SPECT scintigraphy to predict cardio­vascular events in patients with a first AMI. Methods: Patients with a first ST-segment elevation AMI were included from 2009 to 2014. Infarct size was estimated using the Cedars QPS software. The incidence of events (heart failure, ventricular arrhythmias, mortality and a composite of the three events) was evaluated at one year. Results: One-hundred and forty nine patients were included in the study; mean age was 59±11 years and 81.9% were men. Diabetes was present in 16.1% of cases, 9.4% had a history of myocardial revascularization, 84.6% were admitted in Killip and Kimball class A, 43% of AMIs were located in the anterior wall and 69.8% of the patients underwent reperfusion. Left ventricular ejection fraction estimated by gated SPECT scintigraphy was 51%±14%. Follow-up was completed in 95.9% of cases. An IS cutoff point of 22% (ROC curve) was established to predict the composite endpoint at follow-up (sensitivity 92%, specificity 81%, AUC: 0.94%), dividing the sample into two groups: Group I (IS <22%) and Group II (IS ≥22%). The prevalence of the composite endpoint was greater in Group II (2.1% Group I vs. 50% Group II; p<0.001). Infarct size ≥ 22% was the only variable identified as predictor of events during follow-up (OR 1.978; 95% CI 1.887-1.996; p<0.001). Conclusion: Early quantification of IS by gated SPECT scintigraphy is an independent risk predictor at one year that allows risk stratification in patients with a first AMI.

Introducción: Si bien la SPECT de perfusión miocárdica ha mejorado la sensibilidad y la especificidad en la detección del compromiso miocárdico luego de un infarto agudo de miocardio (IAM), aún es escasa la información sobre la determinación precoz del tamaño del infarto (TI) con este método para la estratificación del riesgo y su valor pronóstico. Objetivos: Evaluar la utilidad de la cuantificación del TI estimado por SPECT gatillada en la predicción de complicaciones cardio­vasculares en pacientes con un primer IAM. Material y métodos: Se analizaron los pacientes con IAM con elevación del ST desde 2009 a 2014, excluyéndose aquellos con IAM previo. El cálculo del TI se realizó con el softwareCedars QPS. Se evaluaron eventos al año: insuficiencia cardíaca, arritmias ventri-culares, muerte y la combinación de los tres eventos. Resultados: Se incluyeron 149 pacientes, con edad media de 59±11 años,el 81,9% de sexo masculino. El 16,1% eran diabéticos y el 9,4% presentaban revascularización previa. El 84,6% ingresaron en Killip y Kimball A, el 43% de los IAM fueron de territorio anterior y el 69,8% de los pacientes fueron reperfundidos. La fracción de eyección del ventrículo izquierdo por SPECT gatillada fue del 51% ±14%. Se realizó seguimiento clínico en el 95,9% de los casos. El punto de corte del TI (curva ROC) para predecir eventos combinados al seguimiento se estableció en 22% (sensibilidad: 92%, especificidad: 81%, ABC: 0,94),con el cual la muestra se dividió en dos grupos: Grupo I (TI<22%) y Grupo II (TI≥22%). La prevalencia de eventos combinados fue mayor en el Grupo II (2,1% Grupo Ivs. 50% Grupo II; p<0,001). El TI ≥22% se identificó como la única variable predictora de eventos al seguimiento (OR 1,978; IC 95% 1,887-1,996; p<0,001). Conclusión: La cuantificación precoz del TI mediante SPECT es un predictor independiente de riesgo al año que permite establecer una estratificación del riesgo en pacientes con un primer IAM.

Variables asociadas al restablecimiento de la función ventricular luego de la revascularización miocárdica en pacientes con disfunción sistólica / Variables associated with the restoration of ventricular function after myocardial revascularization in patients with systolic dysfunction / Variáveis associadas com a restauração da função ventricular após a revascularização do miocárdio em pacientes com disfunção sistólica

Introducción. La revascularización miocárdica es el tratamiento de elección en pacientes con disfunción sistólica isquémica. Objetivos. Determinar las variables asociadas al restablecimiento de la fracción de eyección en pacientes con disfunción ventricular isquémica sometidos a revascularización miocárdica. Materiales y métodos. Se incluyeron pacientes con fracción de eyección del ventrículo izquierdo (FEVI) <50% sometidos a cirugía por anatomía coronaria y seguimiento ecocardiográfico ≥6 meses. Se analizaron variables relacionadas con la mejoría de la FEVI (>5%). Resultados. Se incluyeron 95 pacientes, el 91,6% masculino, edad media de 63 años, 40% diabéticos, 27% con infarto previo y FEVI de 36 ± 6%. Se evaluó viabilidad en el 78%. Durante el postoperatorio, el 12% presentó isquemia perioperatoria y el 28% bajo gasto cardíaco. Tras análisis multivariado, la viabilidad y la ausencia de isquemia perioperatoria fueron predictores independientes de la mejoría de la FEVI. Conclusión. La viabilidad y la falta de isquemia durante el perioperatorio se asociaron con mejoría de la FEVI durante el postoperatorio alejado.

Introduction. Myocardial revascularization is considered the best option for patients with ischemic left ventricular dysfunction. Objectives. To identify associated variables with the improvement of ejection fraction after surgical revascularization (CABG). Materials and methods. We included patients with ejection fraction (EF) <50% who underwent to CABG. We examine preoperative predictors of ventricular functional recovery. Results. We included 95 patients, 91.6% male, mean age of 63 years, 40% diabetes, 27% with prior myocardial infarction and EF average of 36 ± 6%. Myocardial viability was evaluated in 78%. After surgery, 12% presented postoperative ischemia and 28% low cardiac output syndrome. In a multivariate analysis, myocardial viability and absence of postoperative ischemia were both predictors of improvement in EF. Conclusion. Myocardial viability and absence of postoperative ischemia were both associated with improvement in post operative EF.

Introdução. A revascularização do miocárdio é considerada a melhor opção para pacientes com disfunção ventricular esquerda isquêmica. Objetivos. Determinar as variáveis associadas à melhora da fração de ejeção (FE) após a revascularização cirúrgica (CRM). Materiais e métodos. Foram incluídos pacientes com FE <50% submetidos à CRM de acordo com a anatomia coronariana e ecocardiográfica ≥6 meses. Foram analisadas as variáveis relacionadas à melhora da FE (>5%). Resultados. Foram incluídos 95 pacientes, 91,6% do sexo masculino, idade média 63 anos, 40% eram diabéticos, 27% com infarto do miocárdio prévio e FE média de 36 ± 6%. A viabilidade miocárdica foi avaliada em 78%. Após a cirurgia, 12% apresentaram isquemia peri-operatória e 28% síndrome de baixo débito cardíaco. Em uma análise multivariada, a viabilidade miocárdica e ausência de isquemia peri-operatória foram ambos preditores de melhora na FE. Conclusão. A viabilidade miocárdica e ausência de isquemia peri-operatória foram ambos associados com a melhora da FE durante o pós-operatório.

[Postpartum pulmonary hypertension]. / Hipertensión pulmonar postparto.

Pulmonary hypertension (PH) in pregnancy is a rare disorder that carries a high risk to mother and child, and as such, it is considered a contraindication to becoming pregnant. However, there are few published reports related to the diagnosis of this condition after delivery. We describe three PH cases diagnosed after their normal pregnancies and deliveries. Although the causes are unknown, several mechanisms such as hypercoagulation, placental hypoxia or amniotic fluid embolism have been considered as possible causes. It is difficult to define whether a PH diagnosed in the postpartum period, relates to an earlier asymptomatic PH period that was triggered by the physiological stress of labor or if it is a recently acquired condition. Despite the lack of data to support the absence of PH previous to pregnancy in our three patients, lack of events during this period, asymptomatic and normal deliveries, lead us to believe that they did not suffer this disease prior to pregnancy; considering that high hemodynamic demands impair a ventricle with little reserve, and its subsequent appearance at time of delivery.